Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir
about
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis CDaclatasvir: potential role in hepatitis CDaclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisSimilar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencingNovel permissive cell lines for complete propagation of hepatitis C virus.Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionPreclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 culturesA Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human HepatocytesComplex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.Therapy for hepatitis C genotype 3: moving forward.Beclabuvir for the treatment of hepatitis C.Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.NS5A inhibitors for the treatment of hepatitis C infection.A small-molecule inhibitor of hepatitis C virus infectivity.Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.Evaluation of antiviral drug synergy in an infectious HCV system.Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model.The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice
P2860
Q26745769-9E7B9A1C-9986-4BBF-84A4-815BA26368AEQ27012741-0F12BEC7-C216-48C9-9B74-C35E8CB8DB13Q28077287-A1A8CF64-66A8-4DD8-8513-6085DD17CA8BQ28542443-20350383-AE2D-41C9-9B66-4177357C0AC7Q33602824-3562B9CA-4A42-4828-A13A-026B24595585Q33672648-D247DA33-46C5-4BAF-A95C-36779EEDAF52Q33797808-8D91A0FC-8170-46E7-A0D3-5AFA9B9983CDQ33798031-AC5AE0F8-D9B2-4C53-B6E1-AE4BAE712545Q34411617-69AB7CAF-4621-4A3E-A8F0-2BB6A2EDC2B8Q34597529-6CD61468-A0B4-4E04-8C23-E0CC6D0C7FACQ34766299-8AE43542-F090-4ADE-9CAC-1464B663EBD1Q36037497-D880049C-7768-4DEE-9AD6-DB2BD39BC33CQ36173242-F9F1EF48-8B7F-425E-96C9-E462E3392C0DQ36667066-DC152DDA-DACC-45E2-83E6-A8F00EA03FC2Q37426527-ADC0DA30-8193-4DED-A966-740C1FE7A197Q38180719-44972DFC-A865-48F1-B412-4CA205A21F33Q38365658-697388BF-0C78-4CD2-93F5-B9916A99AD94Q38476041-CB3AA368-178C-411F-A8B7-A71ABAE7F36AQ38544196-8A718B24-B59E-46A8-B7AF-3E874027A6E2Q38581478-D5958897-BB06-4127-A20D-292824E4E13EQ39031350-9CE400BF-329F-4379-9272-ABC456B06D11Q39069509-F95B2BD2-4242-40EB-8332-57474104F6D1Q39219026-B8F5605E-FD3E-454E-B253-D9F56803D830Q39871877-254EA64E-160B-4512-8215-135A8AF58178Q40081918-0FC6770D-9C33-4EB3-AC81-FE26B3299726Q40773451-E4C928A1-34B5-4B77-A980-5C24CBEC6D99Q41605573-555F5403-8FAA-4038-8434-4E37CBCE4DD5Q42200400-70CCF387-4820-458B-BD6D-E4F88573916DQ58737372-9B336E1D-91FB-4C8F-9FAF-3644B7A5D810
P2860
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Effect on hepatitis C virus re ...... ing NS5A inhibitor daclatasvir
@ast
Effect on hepatitis C virus re ...... ing NS5A inhibitor daclatasvir
@en
type
label
Effect on hepatitis C virus re ...... ing NS5A inhibitor daclatasvir
@ast
Effect on hepatitis C virus re ...... ing NS5A inhibitor daclatasvir
@en
prefLabel
Effect on hepatitis C virus re ...... ing NS5A inhibitor daclatasvir
@ast
Effect on hepatitis C virus re ...... ing NS5A inhibitor daclatasvir
@en
P2093
P2860
P356
P1476
Effect on hepatitis C virus re ...... ing NS5A inhibitor daclatasvir
@en
P2093
Julie A Lemm
Lenore A Pelosi
Mengping Liu
Stacey Voss
P2860
P304
P356
10.1128/AAC.01209-12
P407
P577
2012-07-30T00:00:00Z